Table of Contents :
• Stock Rating & Target Price
• Investment Thesis
• Fundamental Models Used
• Company Description
• Corporate Timeline
• Key Metrics (KPI ) and Recently Reported Earnings Review
• Business Highlights, Strategic Announcements & Outlook
• Quarter-over-Quarter (Q-o-Q) and Year-over-Year (Y-o-Y) Growth Analysis
• Key Catalysts Driving Growth
• Historical Financial Statement Analysis & CAGR Trends
• Quarterly Key Financial Ratios and Performance Metrics
• Annual Financial Performance Analysis: Horizontal and Vertical Financial Analysis, Trends
• Financial Forecasts
• Annual Forecasts: Income Statement
• Annual Forecasts: Cash Flow Statements
• Net Debt Levels
• A Closer Look at DCF: Our Assumptions and Methodology
• Terminal Value Calculation
• Target Price Analysis
• Valuation Multiples
• Supplementary Valuation Analysis: Multiples Approach
• Scenario/Sensitivity Analysis – Base Case , Bull Case ,Bear Case
• Holistic Peer Review & Trading Comps: Financial Data, Operational Metrics, and Valuation Multiples
• Implied Price Per Share
• Ownership Activity/ Insider Trades
• Ownership Summary
• An analysis of ESG Risk Rating
• Key Professionals
• Key Board Members
• Key Risks Considerations
• Analyst Ratings
• Analyst Industry Views
• Disclosures
Alnylam Pharmaceuticals (ALNY): Cardiomyopathy Opportunity as Key Growth lever– Can It COMPETE Effectively and Redefine the Market- What’s the Impact, Outlook, & its 5 Key Competitive and Strategic Catalysts ?
Alnylam Pharmaceuticals continues to assert its leadership in RNAi therapeutics, with strong commercial execution and a robust pipeline underpinning significant growth potential. Through Q3 2024, the company achieved over 30% YoY revenue growth, prompting an upward revision to its full-year guidance to $1.55-$1.625 billion, driven by AMVUTTRA’s best-in-class label and sustained market leadership in ATTR polyneuropathy despite competitive pressure. Looking ahead, the 2025 expansion of AMVUTTRA into the cardiomyopathy market (300,000 patients) represents a transformative opportunity, supported by positive HELIOS-B Phase III data and competitive advantages in dosing, safety, and cost profile. Alnylam’s pipeline offers further upside with zilebesiran, targeting the hypertension market, and next-generation TTRsc04, designed to enhance durability and profitability through royalty savings. Early-stage CNS/ocular programs, including ALN-APP, provide additional platform depth. Financially, Alnylam is on track for non-GAAP profitability by 2025, supported by strong cash reserves and operational discipline aligned with its ambitious “225 strategy.” Near-term drivers include AMVUTTRA’s March 2025 PDUFA date, while long-term success hinges on penetrating the cardiomyopathy market, achieving payer alignment, and advancing its pipeline. Can Alnylam effectively execute on these catalysts to redefine the cardiomyopathy landscape while sustaining leadership in RNAi therapeutics?
